Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.
By Cláudia Saraiva, C. Praça, R. Ferreira, T. Santos, L. Ferreira, L. Bernardino. Journal of Controlled Release, 2016
1,343 citations recorded by the source corpus.
The blood-brain barrier (BBB) is a vital boundary between neural tissue and circulating blood. The BBB's unique and protective features control brain homeostasis as well as ion and molecule movement. Failure in maintaining any of these components results in the breakdown of this specialized multicellular structure and consequently promotes neuroinflammation and neurodegeneration. In several high incidence pathologies such as stroke, Alzheimer's (AD) and Parkinson's disease (PD) the BBB is impaired. However, even a damaged and more permeable BBB can pose serious challenges to drug delivery into the brain. The use of nanoparticle (NP) formulations able to encapsulate molecules with therapeutic value, while targeting specific transport processes in the brain vasculature, may enhance drug transport through the BBB in neurodegenerative/ischemic disorders and target relevant regions in the brain for regenerative processes. In this review, we will discuss BBB composition and characteristics and how these features are altered in pathology, namely in stroke, AD and PD. Additionally, factors influencing an efficient intravenous delivery of polymeric and inorganic NPs into the brain as well as NP-related delivery systems with the most promising functional outcomes will also be discussed.
Subfields: Biomaterials, Neurology, Pharmaceutical Science
View Paper: https://www.semanticscholar.org/paper/fe421a73ac68bc591ff2569dad33593f2435f7fb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
Citations in the corpus
- Current Strategies for Brain Drug Delivery (2018, background): “Extensive reviews can be found elsewhere [29-31].”
- The blood–brain barrier: Structure, regulation and drug delivery (2023, background): “30,31 Capillaries are the major site of the BBB.”
- Current Challenges and Opportunities in Treating Glioblastoma (2018, background): “…4) able to target macromolecules on the cell membrane directly such as peptides (e.g., RGD, NGR, and pep-1 peptides), proteins (transferrin), and antibodies (e.g., nicotinic acetylcholine receptor, EGFR, IL13Ra2, and LRP1 antibodies) (Wiley et al., 2013; Shilo et al., 2014; Saraiva et al., 2016).”